

# Common Genetic Variation Near the *Phospholamban* Gene Is Associated with Cardiac Repolarisation: Meta-Analysis of Three Genome-Wide Association Studies

Ilja M. Nolte<sup>1</sup>, Chris Wallace<sup>2</sup>, Stephen J. Newhouse<sup>2</sup>, Daryl Waggott<sup>3</sup>, Jingyuan Fu<sup>1,4</sup>, Nicole Soranzo<sup>5,6</sup>, Rhian Gwilliam<sup>5</sup>, Panos Deloukas<sup>5</sup>, Irina Savelieva<sup>7</sup>, Dongling Zheng<sup>8</sup>, Chrysoula Dalageorgou<sup>8</sup>, Martin Farrall<sup>9</sup>, Nilesh J. Samani<sup>10</sup>, John Connell<sup>11</sup>, Morris Brown<sup>12</sup>, Anna Dominiczak<sup>11</sup>, Mark Lathrop<sup>13</sup>, Eleftheria Zeggini<sup>5,14</sup>, Louise V. Wain<sup>15</sup>, for the The Wellcome Trust Case Control Consortium<sup>1a</sup>, The DCCT/EDIC Research Group<sup>1b</sup>, Christopher Newton-Cheh<sup>16,17,18</sup>, Mark Eijgelsheim<sup>19</sup>, Kenneth Rice<sup>20</sup>, Paul I. W. de Bakker<sup>17,21</sup> for the QTGEN consortium<sup>1c</sup>, Arne Pfeufer<sup>22,23</sup>, Serena Sanna<sup>24</sup>, Dan E. Arking<sup>25</sup>, for the QTSCD consortium<sup>1d</sup>, Folkert W. Asselbergs<sup>1,26</sup>, Tim D. Spector<sup>6</sup>, Nicholas D. Carter<sup>8</sup>, Steve Jeffery<sup>8</sup>, Martin Tobin<sup>15</sup>, Mark Caulfield<sup>2</sup>, Harold Snieder<sup>1,6</sup>, Andrew D. Paterson<sup>27</sup>, Patricia B. Munroe<sup>29</sup>, Yalda Jamshidi<sup>8,9,\*</sup>

**1** Unit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, **2** Clinical Pharmacology and Barts and the London Genome Centre, William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom, **3** Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, **4** Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, **5** Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, **6** Department of Twin Research and Genetic Epidemiology Unit, St Thomas' Campus, King's College London, St Thomas' Hospital, London, United Kingdom, **7** Cardiological Sciences, Division of Cardiac and Vascular Sciences, St George's University of London, London, United Kingdom, **8** Division of Clinical Developmental Sciences, St George's University of London, London, United Kingdom, **9** Department of Cardiovascular Medicine, University of Oxford, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom, **10** Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, United Kingdom, **11** BHF Glasgow Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, University of Glasgow, Western Infirmary, Glasgow, United Kingdom, **12** Clinical Pharmacology and the Cambridge Institute of Medical Research, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom, **13** Centre National de Genotypage, Evry, France, **14** The Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom, **15** Departments of Health Sciences & Genetics, University of Leicester, Leicester, United Kingdom, **16** Center for Human Genetic Research, Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America, **17** Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America, **18** NHLBI's Framingham Heart Study, Framingham, Massachusetts, United States of America, **19** Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands, **20** Department of Biostatistics, University of Washington, Seattle, Washington, United States of America, **21** Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School-Partners HealthCare Center for Genetics and Genomics, Boston, Massachusetts, United States of America, **22** Institute of Human Genetics, Technical University Munich, Munich, Germany, **23** Institute of Human Genetics, Helmholtz Center Munich, Munich, Germany, **24** Istituto di Neurogenetica e Neurofarmacologia, CNR, Monserrato, Cagliari, Italy, **25** McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, **26** Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, **27** Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, Ontario, Canada

## Abstract

To identify loci affecting the electrocardiographic QT interval, a measure of cardiac repolarisation associated with risk of ventricular arrhythmias and sudden cardiac death, we conducted a meta-analysis of three genome-wide association studies (GWAS) including 3,558 subjects from the TwinsUK and BRIGHT cohorts in the UK and the DCCT/EDIC cohort from North America. Five loci were significantly associated with QT interval at  $P < 1 \times 10^{-6}$ . To validate these findings we performed an *in silico* comparison with data from two QT consortia: QTSCD ( $n = 15,842$ ) and QTGEN ( $n = 13,685$ ). Analysis confirmed the association between common variants near *NOS1AP* ( $P = 1.4 \times 10^{-83}$ ) and the phospholamban (*PLN*) gene ( $P = 1.9 \times 10^{-29}$ ). The most associated SNP near *NOS1AP* (rs12143842) explains 0.82% variance; the SNP near *PLN* (rs11153730) explains 0.74% variance of QT interval duration. We found no evidence for interaction between these two SNPs ( $P = 0.99$ ). *PLN* is a key regulator of cardiac diastolic function and is involved in regulating intracellular calcium cycling, it has only recently been identified as a susceptibility locus for QT interval. These data offer further mechanistic insights into genetic influence on the QT interval which may predispose to life threatening arrhythmias and sudden cardiac death.

**Citation:** Nolte IM, Wallace C, Newhouse SJ, Waggott D, Fu J, et al. (2009) Common Genetic Variation Near the *Phospholamban* Gene Is Associated with Cardiac Repolarisation: Meta-Analysis of Three Genome-Wide Association Studies. *PLoS ONE* 4(7): e6138. doi:10.1371/journal.pone.0006138

**Editor:** Peter M. Visscher, Queensland Institute of Medical Research, Australia

**Received:** May 12, 2009; **Accepted:** June 4, 2009; **Published:** July 9, 2009

**Copyright:** © 2009 Nolte et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** For TwinsUK: This study was funded by the British Heart Foundation, Project grant No. 06/094. The study was also funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F2-2008-201865-GEFOS and (FP7/2007-2013), ENGAGE project grant agreement HEALTH-F4-2007-201413 and the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254). The study also receives support from the Dept of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London. TDS is an NIHR senior Investigator. The project also received support from a Biotechnology and Biological Sciences Research Council (BBSRC) project grant(G20234). The authors acknowledge the funding and support of the National Eye Institute via an NIH/CIDR genotyping project (PI: Terri Young). CD is supported by a British Heart Foundation grant: SP/02/001. For the BRIGHT study: The BRIGHT study is supported by the Medical Research Council of Great Britain (grant number; G9521010D) and the British Heart Foundation (grant number PG02/128). CW was funded by the British Heart Foundation (grant number: FS/05/061/19501). SJN is funded by the Medical Research Council and The William Harvey Research Foundation. Profs Dominiczak and Samani are British Heart Foundation Chairholders. EZ is funded by the Wellcome Trust (WT088885/Z/09/Z). For the DCCT/EDIC study: The DCCT/EDIC Research Group is sponsored through research contracts from the National Institute of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institutes of Health. The authors are grateful to the subjects in the DCCT/EDIC cohort for their long-term participation. A.D.P. holds a Canada Research Chair in the Genetics of Complex Diseases. This work has received support from National Institute of Diabetes and Digestive and Kidney Diseases Contract N01-DK-6-2204, National Institute of Diabetes and Digestive and Kidney Diseases Grant R01-DK-077510 and support from the Canadian Network of Centres of Excellence in Mathematics and Genome Canada through the Ontario Genomics Institute. For QTSCD: ARIC is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022, R01HL087641, R01HL59367 and R01HL086694; National Human Genome Research Institute contract U01HG004402; and National Institutes of Health contract HHSN268200625226C. Infrastructure was partly supported by Grant Number UL1RR025005, a component of the National Institutes of Health and NIH Roadmap for Medical Research. In addition, we acknowledge support from NHLBI grants HL86694 and HL054512, and the Donald W. Reynolds Cardiovascular Clinical Research Center at Johns Hopkins University for genotyping and data analysis relevant to this study. AK is supported by a German Research Foundation Fellowship. The KORA study was funded by the State of Bavaria and by grants from the German Federal Ministry of Education and Research (BMBF) in the context of the German National Genome Research Network (NGFN), the German National Competence network on atrial fibrillation (AFNET) and the Bioinformatics for the Functional Analysis of Mammalian Genomes program (BFAM) by grants to Stefan Kaab (NGFN 01GS0499, 01GS0838 and AF-Net 01GI0204/N), Arne Pfeufer (NGFN 01GR0803, 01EZ0874), H.-Erich Wichmann (NGFN 01GI0204) and to Thomas Meitinger (NGFN 01GR0103). Stefan Kaab is also supported by a grant from the Fondation Leducq. The SardinIA team was supported by Contract N01-AG-1-2109 from the National Institute on Aging contract N01-AG-1-2109 to the SardinIA ("ProgeNIA") team and in part by the Intramural Research Program of the US National Institute on Aging, NIH. The efforts of G.R.A. were supported in part by contract 263-MA-410953 from the National Institute on Aging to the University of Michigan and by research grants from the National Human Genome Research Institute and the National Heart, Lung, and Blood Institute (to G.R.A.). The GenNOVA study was supported by the Ministry of Health of the Autonomous Province of Bolzano and the South Tyrolean Sparkasse Foundation. The Heinz Nixdorf Recall Study was funded by a grant of the Heinz Nixdorf Foundation (Chairman: Dr. jur. G. Schmidt). For QTGEN: The Framingham Heart Study work was supported by the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine (Contract No. N01-HC-25195), its contract with Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278), and the Doris Duke Charitable Foundation (C.N.-C.) and Burroughs Wellcome Fund (C.N.-C.), based on analyses by Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. The measurement of ECG intervals in Framingham Heart Study generation 1 and 2 samples was performed by eResearchTechnology and was supported by an unrestricted grant from Pfizer. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The generation and management of GWAS genotype data for the Rotterdam Study is supported by the Netherlands Organisation of Scientific Research NWO Investments (#175.010.2005.011, 911-03-012). This study is funded by the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project #050-060-810. The CHS research reported in this article was supported by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, grant numbers U01 HL080295 and R01 HL087652 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. C.N.-C. is supported by NIH K23-HL-080025, a Doris Duke Charitable Foundation Clinical Scientist Development Award, and a Burroughs Wellcome Fund Career Award for Medical Scientists. M.E is funded by the Netherlands Heart Foundation 2007B221. J.I.R. is supported by the Cedars-Sinai Board of Governors' Chair in Medical Genetics. The measurement of ECG intervals in the Framingham Heart Study generation 3 sample was completed by Alim Hirji and Sirisha Kovvali using AMPs software provided through an unrestricted academic license by AMPs, LLC (New York, NY). USAA full list of principal CHS investigators and institutions can be found at <http://www.chs-nhlbi.org/pi.htm>. The authors acknowledge the essential role of the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium in development and support of this manuscript. CHARGE members include the Netherlands Rotterdam Study, the NHLBI's Atherosclerosis Risk in Communities (ARIC) Study, Cardiovascular Health Study (CHS) and Framingham Heart Study (FHS), and the NIA's Iceland Age, Gene/Environment Susceptibility (AGES) Study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** Aravinda Chakravarti is a paid member of the Scientific Advisory Board of Affymetrix, a role that is managed by the Committee on Conflict of Interest of the Johns Hopkins University School of Medicine.

\* E-mail: yjamshidi@sgul.ac.uk

¶ These authors contributed equally to this work.

¶<sup>a</sup> For the full author list see Appendix S1.

¶<sup>b</sup> A complete list of investigators and members of the DCCT/EDIC Research Group appears in *N Engl J Med* 2005; 353(25):2643–53.

¶<sup>c</sup> A complete list of investigators and members of the QTGEN consortium appears in Appendix S1.

¶<sup>d</sup> A complete list of investigators and members of the QTSCD consortium appears in Appendix S1.

## Introduction

The QT interval on the electrocardiogram (ECG) represents the period of ventricular depolarization and subsequent repolarisation. Individuals with delayed cardiac repolarisation show a longer QT interval and this predisposes them to the development of cardiac arrhythmias. Patients with the rare Mendelian Long QT Syndrome (LQTS) are at risk of sudden cardiac death [1]. Lengthening of the heart-rate corrected QT interval within the normal range is

associated with increased coronary heart disease incidence and mortality, as well as all-cause mortality [2,3]. QT prolongation is the most common cause for withdrawal or restriction of drugs that have already been marketed. Furthermore, many potentially valuable drugs fail to be approved or are downgraded to second-line status because they prolong QT and increase risk of serious life threatening arrhythmias, especially torsade de pointes [4].

QT interval length is known to be influenced by various parameters such as heart rate [5], age [6], sex [7], and medications

**Table 1.** Study characteristics of the TwinsUK, BRIGHT and DCCT/EDIC cohorts.

	TwinsUK	BRIGHT	DCCT/EDIC
N	1,048	1,392	1,118
Age, mean (SD)	51.8 (12.0)	56.7 (10.9)	46.0 (7.0)
Sex, n (%) male	12 (1.1)	502 (36.0)	568 (51.0)
QT interval, mean (SD)	400.9 (27.9)	414.5 (33.8)	387.6 (29.2)
<sup>a</sup> Hypertensive, %	21.8	100	50.8
<sup>b</sup> Diabetic, %	3.1	0	100

<sup>a</sup>Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg or taking anti-hypertensive drugs.

<sup>b</sup>Type 1 or type 2 diabetes.

doi:10.1371/journal.pone.0006138.t001

[8], and studies have suggested that QT interval at the population level is a genetically influenced quantitative trait with up to 52% heritability [9–11]. Until recently, research into genetic factors influencing QT interval was limited to candidate genes known to have a role in arrhythmogenesis on the basis of their involvement in Mendelian Long or Short-QT Syndrome (LQTS or SQTs) [12–17]. However, an early genome-wide association (GWA) study [18] identified a common genetic variant (rs10494366) in the nitric oxide synthase 1 adaptor protein (*NOS1AP*) gene region, which has been consistently associated with QT-interval variation across many independent replication studies [19–24]. The *NOS1AP* variant has been estimated to explain up to 1.5% of QT variance [18], therefore larger GWA studies of QT interval have the potential to detect additional common genetic variants, likely of more modest effect size. Recently, two consortia (QTGEN [25] and QTSCD [26]) reported meta-analyses of GWAS of QT interval duration in population-based cohorts, these papers describe a number of new loci [25,26].

We report a meta-analysis of three GWA studies totalling 3,558 individuals and test for association between QT interval duration and approximately 2.4 million genotyped or imputed single nucleotide polymorphisms (SNPs). Subsequently, we performed an *in silico* comparison for our five most significant SNPs with QTGEN (n = 13,685) [25] and QTSCD (n = 15,842) [26]. Our results confirm the known association with the *NOS1AP* locus and QT interval duration, more importantly it confirms the recently reported association of variants near the *PLN* locus [25,26]. We found no evidence of gene-gene interaction between *NOS1AP* and *PLN*.


## Results and Discussion

### Meta-analysis results from TwinsUK, BRIGHT and DCCT/EDIC cohorts


The characteristics of the 3,558 individuals included in the meta-analysis are shown in Table 1. Genome wide genotyping was performed using a variety of platforms; therefore we imputed genotypes using the HapMap CEU sample. A total of 2,399,142 genotyped or imputed SNPs met the inclusion criteria for our study; we tested these for association with QT interval using an additive model. We observed highly associated SNPs in five chromosomal regions 1q23.3, 6q22.31, 13q13, 20p13 and 21q21.3 (Figure 1). Possible bias caused by population stratification was checked by calculating the genomic inflation factor  $\lambda$  of the meta-analysis [27,28]. The  $\lambda$  was 1.016 indicating our samples showed little evidence for population stratification and therefore the results of the meta-analysis were not adjusted (Figure 2). Table 2 shows the results by cohort of the most significant SNP for each associated region, Table S1 shows the results for all SNPs with  $P < 1 \times 10^{-6}$ . One SNP (rs885170) near *NBEA* on chromosome 13 exceeded the genome-wide significance threshold,  $P = 5 \times 10^{-8}$  based on recent estimations of the genome-wide testing burden for common sequence variation [29,30]. Four other SNPs had  $P < 1 \times 10^{-6}$ . The first was rs12143842 ( $P = 2.1 \times 10^{-7}$ ), it is located on chromosome 1, upstream of *NOS1AP*, a gene already identified as prolonging QT interval [18]. The second SNP rs2832357 ( $P = 2.3 \times 10^{-7}$ ) is located on chromosome 21, near *GRIK1*, the third rs11153730 ( $P = 6.4 \times 10^{-7}$ ) is located on chromosome 6 in an intergenic region in a cluster of SNPs near three genes *SLC35F1*, *C6orf204* and *PLN*. The final locus, rs6038729 ( $P = 6.3 \times 10^{-7}$ ) is located on chromosome 20, near the *BMP2* gene.

### Results for known LQTS and SQTs candidate genes

There are 11 genes identified to date as being causative for Mendelian single gene forms of LQTS and SQTs. Notably, both of the recent GWAS meta-analyses [25,26] found that common variants in a subset of these genes encoding ion channels, known to cause the Mendelian LQTS, were the most strongly associated with QT interval. We looked up the SNP with the lowest P-value in each of these genes and up to 20 kb upstream and downstream. Only one SNP in *KCNE1* (LQT5; rs3787730 A>G; frequency allele A: 31.7%;  $\beta \approx -1.6$  ms/allele A;  $P = 0.00045$ ; Table S2) was found to be significantly associated with QT interval, although not genome-wide significant. This SNP was not in linkage disequilibrium with the polymorphisms D85N (rs1805128;  $r^2 = 0.011$ ;



**Figure 1.** Manhattan plot for QT interval based on GWAS meta-analysis of TwinsUK, BRIGHT, and DCCT/EDIC cohorts. SNPs are ordered along the chromosomes on the x-axis. The  $-\log_{10}(P)$  results are plotted for 2,399,142 SNPs of the meta-analysis of TwinsUK, BRIGHT and DCCT/EDIC cohorts for 3,558 individuals. The red dots indicate SNPs with  $P < 10^{-6}$ . doi:10.1371/journal.pone.0006138.g001



**Figure 2. Quantile-quantile plots of association results of the meta-analysis from TwinsUK, BRIGHT and DCCT/EDIC cohorts.** Based on 2,399,142 SNPs in 3,558 individuals from the combined cohorts. The  $-\log_{10}(P)$  plot of association test for QT interval is shown for all SNPs (black diamonds) and for all SNPs except those located within 1 Mb of the most significant SNPs of our five associated regions (dark grey) [26]. Genomic Control  $\lambda$  was 1.016 [25]. The lower horizontal line denotes the 95% percentile of the results of all SNPs, values lower than this threshold were used for calculating the  $\lambda$ . The upper line indicates the point from where P-values of the complete dataset deviate from the expected line.  
doi:10.1371/journal.pone.0006138.g002

$P = 0.87$ ) and rs727957 ( $r^2 = 0.010$ ;  $P = 0.090$ ), which were previously found to be associated with prolonged QT interval in a general population [14,31]. None of the other genes showed evidence for association with QT interval in our study.

### Follow-up of the top 5 loci

To validate potential associations with QT interval we selected the most associated SNP in each of the five regions from the primary meta-analysis and conducted an *in silico* comparison with data from the QTSCD and QTGEN consortia (Table 3). This confirmed two of our five loci as being significantly associated with QT interval in the replication at  $P = 5 \times 10^{-8}$ ; the strongest evidence of association was with a SNP near *NOS1AP*, rs12143842 ( $P = 1.4 \times 10^{-83}$ ). rs10494366 is the *NOS1AP* polymorphism most commonly associated with QT interval in previous studies [19–24], it reached a P-value of 0.035 in our data-set. This SNP is not strongly correlated to rs12143842 in the HapMap CEU samples ( $r^2 = 0.102$ ). The rs12143842 polymorphism explains 0.82% variance of QT interval in our meta-analysis.

The second significantly associated locus was at chromosome 6q22.31, near the *SLC35F1/C6orf204/PLN* loci (rs11153730;  $P = 1.9 \times 10^{-29}$ , Table 3; Figure 3). This SNP is intergenic in a region with only a few genes. Little is known about *SLC35F1* and *C6orf204*, however the most plausible candidate gene is phospholamban (*PLN*), an inhibitor of the  $\text{Ca}^{2+}$ -ATPase isoform 2a (SERCA2a), a  $\text{Ca}^{2+}$  transporting intracellular pump located in the sarcoplasmic reticulum (SR) of cardiac muscle cells. The most associated SNP rs11153730 is strongly correlated with two intronic

SNPs (rs3752581 and rs13192336) in *PLN* ( $r^2$  of 0.7 in HapMap CEU samples). Both SNPs are associated with QT interval  $P = 7.3 \times 10^{-4}$ ; both imputed.

The frequency of the C allele of rs11153730 near *PLN* was consistent across studies (48.4% in TwinsUK; 48.1% in BRIGHT; 49.0% in DCCT/EDIC). Each C allele prolongs the standardized QT interval by 0.122 units (corresponding to  $\sim 2.5$  ms) and explains 0.74% variance of QT interval duration (Table 2). The effect size from combining all studies was lower, 0.09 with 0.40% explained variance (Table 3). This decrease in effect size is not unexpected and may be attributed to the “winner’s curse” phenomenon [32].

The effects of the *NOS1AP* and *PLN* loci did not show significant heterogeneity between the three studies as tested by the Q test ( $P > 0.05$ , Table S1) [33], in total the two most significant loci in our initial meta-analysis explain c. 1.6% of the variance in QT interval duration. We also investigated whether there was any evidence for a gene-gene interaction between the two most significantly associated SNPs in the *NOS1AP* (rs12143842) and *PLN* (rs11153730) genes. Analysis revealed no evidence to suggest this ( $P = 0.99$ ).

### Phospholamban and QT interval length

Phospholamban (in its unphosphorylated state) is an inhibitor of the  $\text{Ca}^{2+}$ -ATPase isoform 2a (SERCA2a), a  $\text{Ca}^{2+}$  transporting intracellular pump located in the SR of cardiac muscle cells. The SR controls contraction and relaxation by regulating intracellular calcium levels. Phosphorylation of PLN reduces inhibition of SERCA2a, leading to activation of the  $\text{Ca}^{2+}$  pump, enhanced muscle relaxation rates and decreased  $\text{Ca}^{2+}$  levels, thereby contributing to the contractile response elicited by beta-agonists [34,35].

*PLN* knock-out mice exhibit increased rates of basal myocardial contraction as well as increased rates of basal myocardial relaxation [34,35]. However, the enhanced contractility observed with *PLN* knockout mice is in contrast to humans lacking PLN who develop a lethal cardiomyopathy. Indeed, several rare (non-HapMap) mutations in the human *PLN* gene have been associated with either dilated [36] or hypertrophic cardiomyopathy [37], presumably caused by PLN mediated over-inhibition [38,39] or chronic activation of SERCA2a [37] respectively. Interestingly, some of the individuals in the study of Haghghi *et al.* [40] who were heterozygous for an Arg14Del mutation presented with ventricular extra systolic beats and ventricular tachycardia.

It has previously been shown that prolongation of cardiac repolarization elevates intracellular  $\text{Ca}^{2+}$ , potentially increasing the risk of arrhythmias [41]. Del Monte *et al.* [42] reported that over-expression of SERCA2a in rats reduced ventricular arrhythmias in an ischemia/reperfusion model. Recent evidence showed that intracellular  $\text{Ca}^{2+}$  may also influence  $\text{K}^+$  currents and, thus duration of the action potential [43]. Suppression of SERCA2a by PLN may reduce SR  $\text{Ca}^{2+}$  content and lead to QT interval shortening through calmodulin kinase II-dependent alterations in  $\text{K}^+$  currents [44], whereas SERCA2a over-expression may result in an increased  $\text{Ca}^{2+}$  content and QT interval prolongation as shown in mice without underlying cardiac disease [43].

In addition to PLN, neuronal nitric oxide synthase (NOS1) is also involved in regulating intracellular calcium cycling [45]. NOS1AP is a regulator of NOS1. Furthermore, a recent study of transgenic mice with cardiomyocyte-specific *NOS1* over-expression suggested that the greater intracellular  $\text{Ca}^{2+}$  transients, and SR  $\text{Ca}^{2+}$  load in these mice following treatment to induce cardiac hypertrophy could be explained, at least in part, by modulation of PLN phosphorylation status [46]. In fact, nNOS-derived NO has

**Table 2.** Results of the most significant SNP from the five regions associated with QT interval in GWAS meta-analysis of TwinsUK, BRIGHT and DCCT/EDIC cohorts.

SNP ID	Cohort	Coded Allele Frequency (%)	HWE (P)	Genotyped	Beta (SE)	R <sup>2</sup> (%) <sup>a</sup>	P-value
rs12143842, chr 1	TwinsUK	24.4	0.11	No	0.22 (0.053)	1.76	3.2×10 <sup>-5</sup>
coded allele: T	BRIGHT	26.6	0.89	No	0.15 (0.046)	0.83	0.0015
non-coded allele: C	DCCT/EDIC	25.3	0.68	Yes	0.085 (0.049)	0.27	0.082
	<b>Meta</b>	25.5	N/A	N/A	0.15 (0.028)	0.82	<b>2.1×10<sup>-7</sup></b>
rs11153730, chr 6	TwinsUK	48.4	0.024	No	0.21 (0.145)	2.19	3.6×10 <sup>-6</sup>
coded allele: C	BRIGHT	48.1	0.45	No	0.096 (0.04)	0.46	0.017
non-coded allele: T	DCCT/EDIC	49	0.75	No	0.075 (0.042)	0.28	0.076
	<b>Meta</b>	48.5	N/A	N/A	0.12 (0.024)	0.74	<b>6.4×10<sup>-7</sup></b>
rs885170, chr13	TwinsUK	18.7	0.28	No	0.17 (0.058)	0.84	0.0045
coded allele: G	BRIGHT	19.7	0.41	No	0.22 (0.051)	1.58	1.2×10 <sup>-5</sup>
non-coded allele: A	DCCT/EDIC	17.6	0.76	No	0.14 (0.057)	0.55	0.016
	<b>Meta</b>	18.8	N/A	N/A	0.18 (0.032)	0.99	<b>1.8×10<sup>-8</sup></b>
rs6038729, chr20	TwinsUK	32.3	0.98	Yes	0.064 (0.046)	0.18	0.16
coded allele: C	BRIGHT	30.1	0.14	No	0.21 (0.044)	1.87	2.1×10 <sup>-6</sup>
non-coded allele: A	DCCT/EDIC	32.3	0.78	Yes	0.11 (0.046)	0.54	0.015
	<b>Meta</b>	31.4	N/A	N/A	0.13 (0.026)	0.73	<b>6.3×10<sup>-7</sup></b>
rs2832357, chr 21	TwinsUK	2.7	0.77	Yes	0.27 (0.16)	0.37	0.088
coded allele: G	BRIGHT	2.8	0.2	No	0.49 (0.12)	1.29	5.3×10 <sup>-5</sup>
non-coded allele: A	DCCT/EDIC	2.6	0.21	Yes	0.38 (0.13)	0.71	0.0031
	<b>Meta</b>	2.7	N/A	N/A	0.40 (0.076)	0.82	<b>2.3×10<sup>-7</sup></b>

HWE: Hardy-Weinberg equilibrium test; SE: standard error; N/A: not applicable.

<sup>a</sup>Percentage of explained variance.

doi:10.1371/journal.pone.0006138.t002

**Table 3.** Results of the five most significant loci from GWAS meta-analysis of TwinsUK, BRIGHT and DCCT/EDIC cohorts and *in silico* comparison with the QTGEN and QTSCD consortia data.


SNP	Chr	Position <sup>a</sup>	Flanking genes (distance to SNP in kb)	Coded Allele	Meta-analysis of TwinsUK, BRIGHT and DCCT/EDIC	QTSCD	QTGEN	META
rs12143842	1	160,300,514	<i>OLFML2B</i> ; <i>NOS1AP</i> (-40.2; 5.7)	Freq T (%)	26	24	26	25
				Beta	0.15	0.16	0.21	0.18
				P-value	2.1 10 <sup>-7</sup>	1.6 10 <sup>-35</sup>	8.1 10 <sup>-46</sup>	<b>1.4 10<sup>-83</sup></b>
rs11153730	6	118,774,215	<i>SLC35F1</i> ; <i>C6orf204</i> ; <i>PLN</i> (-28.7; intronic; 202.0)	Freq C (%)	48	50	50	50
				Beta	0.12	0.091	0.08	0.09
				P-value	6.4 10 <sup>-7</sup>	5.2 10 <sup>-16</sup>	5.3 10 <sup>-10</sup>	<b>1.9 10<sup>-29</sup></b>
rs885170	13	34,095,789	<i>RFC3</i> ; <i>NBEA</i> (-657.1; 318.7)	Freq G (%)	19	20	20	20
				Beta	0.18	-0.011	-0.0051	0.01
				P-value	1.8 10 <sup>-8</sup>	0.44	0.76	<b>0.28</b>
rs6038729	20	7,085,757	<i>BMP2</i> ; <i>FUSIP1P2</i> (-367.8; 675.3)	Freq C (%)	31	32	31	32
				Beta	0.13	0.020	-0.0042	0.023
				P-value	6.3 10 <sup>-7</sup>	0.085	0.76	<b>0.0071</b>
rs2832357	21	29,785,765	<i>BACH1</i> ; <i>GRIK1</i> (-129.7; 45.4)	Freq G (%)	3	3	3	3
				Beta	0.40	0.0075	0.022	0.053
				P-value	2.3 10 <sup>-7</sup>	0.82	0.58	<b>0.031</b>

Freq: allele frequency.

<sup>a</sup>NCBI Genome build 36.3.

doi:10.1371/journal.pone.0006138.t003





**Figure 3. Regional association plot for the *SLC35F1/C6orf204/PLN* locus on chromosome 6.** Shown is the region extending to 500 kb either side of the most associated SNP rs11153730. The SNPs are illustrated on  $-\log_{10}(P)$  scale as a function of chromosomal position (NCBI build36.3). The sentinel SNP is illustrated in blue. Surrounding SNPs are coloured according to their  $r^2$  with rs11153730 (red indicates an  $r^2 > 0.8$ , orange an  $r^2$  of 0.5–0.8, yellow an  $r^2$  of 0.2–0.5 and grey an  $r^2$  of less than 0.2). doi:10.1371/journal.pone.0006138.g003

been shown to regulate myocardial relaxation and intracellular  $\text{Ca}^{2+}$  decay by promoting PKA-mediated PLN phosphorylation [47] and in  $\text{nNOS}^{-/-}$  myocytes, decreased PLN phosphorylation has been shown to decrease the rate of SR  $\text{Ca}^{2+}$  reuptake and impair relaxation by inhibiting SERCA2a activity. Whether abovementioned mechanisms are similar in humans awaits confirmation in future studies.

In addition to interaction with the SERCA genes (*ATP2A1* and *ATP2A2*) and NOS1, it has also been suggested that PLN interacts at the protein level with a number of molecules involved in ATP-dependent transport of  $\text{Ca}^{2+}$  (Figure S1). Furthermore, PLN is highly expressed in muscle and heart tissue and is co-expressed with muscle, or heart specific genes (Figures S2 and S3). Together with the data described above these observations suggest that PLN is most likely to influence QT interval through regulation of myocellular calcium cycling.

The current findings indicate that maintaining normal homeostatic calcium cycling is crucial as when imbalanced it can lead to human heart failure. However, *PLN* may also play a role in cardiac repolarization, which again if disturbed leads to serious arrhythmias. Earlier studies have suggested screening for *PLN* mutations in individuals with dilated cardiomyopathy [48,49]. In view of the fact that both super-inhibition, as well as, over-expression of SERCA2a by *PLN* may lead to cardiomyopathy and heart failure,

it maybe that any therapies directed at *PLN* will be challenging to develop without disturbing the fine balance between SERCA2a and *PLN*.

Apart from the discovery of variants in genes causing LQTS and SQTs [13,14,25,26,50] and *NOS1AP* [18–26], very few variants have thus far been consistently associated with QT interval duration in the general population. Our study with 3,558 individuals illustrates the potential of GWAS to identify novel variants playing a role in determining QT interval duration. Our results highlight the consistent role of *NOS1AP* genetic variants in modulating QT interval and confirm the recently identified *PLN* locus. Despite only two loci reaching genome-wide significance overall, and their effects, although positive are modest (<1% of variance), these results must be considered in the context of our sample size. Meta-analyses of larger datasets will no doubt identify additional SNPs with smaller effects or with rarer allele frequencies associated with QT interval.

In summary, our study is amongst the first to report common variants near *PLN* associated with QT interval. Functional relevance of *PLN* to QT interval duration is supported, it has a well documented role in myocellular calcium cycling, our results suggest that further molecular and functional analyses of this gene is warranted to pursue its role in regulating QT interval duration. Furthermore, genetic variation in the *NOS1AP* gene has also been

associated with risk of mortality in patients using both cardiac and non-cardiac drugs [51,52]. Therefore the observed association between *PLN* and *QT* interval may also have implications for cardiac and non-cardiac drug development, as *QT* prolongation is a very common reason for cessation of development or withdrawal of drugs. Further investigation into the potential interaction between *PLN* variants and drug-induced *QT* prolongation would also be of great interest.

## Materials and Methods

### Ethics Statement

All subjects involved in the study gave fully informed written consent for the collection of samples and subsequent analysis. The TwinsUK study received written ethical approval for this study from the National Research Ethics Service (St. Thomas' Research Ethics Committee Ref. EC04/015). The BRIGHT study received written ethical approval from The London Multicentre Research Ethics Committee. The DCCT/EDIC study received written ethical approval from The Hospital for Sick Children Research Ethics Board.

### Study subjects and SNP genotyping

**The TwinsUK Study.** Samples from the TwinsUK cohort were genotyped with the Infinium assay (Illumina, San Diego, USA) across three fully compatible SNP arrays, the Hap300 Duo, Hap300, and Hap550 [53]. SNP calling was performed using the Illuminus software [54]. SNPs were excluded if they violated Hardy–Weinberg equilibrium (HWE) ( $p < 1.0 \times 10^{-4}$ ); had genotype call rates  $< 90\%$ ; or had a minor allele frequency (MAF) of less than 0.01. Individuals were excluded if the sample call rate was less than 95%, autosomal heterozygosity was not between 33 and 37%, genotype concordance was over 97% with another sample and the sample was of lesser call rate, non-caucasian ancestry either self-identified or identified by cluster analysis in STRUCTURE [55], or unexplained relatedness (estimated proportion of allele shared identical by descent  $> 0.05$  [56]) to  $> 120$  other samples. This resulted in GWAS data being available on 305,912 SNPs for 2,256 individuals from 595 dizygotic (DZ) twin pairs and 1066 singletons (among them twins from monozygotic (MZ) twin pairs) from the TwinsUK cohort. This cohort was previously shown to be representative of the general (singleton) UK population [57]. ECG data were available on 1,104 of these individuals. Eight hundred and sixty had automated measurements of the *QT* interval by the Cardiofax ECG-9020K (Nihon Kohden UK Ltd., Middlesex, UK) and 244 were scored manually using a high-resolution digitizing board (GTCO CalComp Peripherals, USA).

Fifty six individuals were removed from the data set because of atrial fibrillation, *QRS* duration  $> 120$  ms or presence of a heart condition (i.e. ischemic heart disease, stroke or bypass surgery). None of the genotyped twins had a pacemaker or used anti-arrhythmic drugs. The dataset for analyses consequently included 1,048 individuals, of which 588 were DZ twins (i.e. 294 pairs) and 460 singletons. These singletons included 235 MZ twins of which the mean *QT* interval of both twins was used to optimise information.

**The BRIGHT study.** Two thousand unrelated white European hypertensive individuals from the BRIGHT study ([www.brightstudy.ac.uk](http://www.brightstudy.ac.uk)) were genotyped with the GeneChip Human Mapping 500K Array Set (Affymetrix). Only individuals and SNPs passing WTCCC thresholds for quality control [58] were included in the analysis. Briefly, individuals were excluded if they had  $> 3\%$  missing data or evidence of non-Caucasian ancestry under Eigenstrat analysis [59]. SNPs were excluded if they showed deviation from HWE

( $p < 5 \times 10^{-7}$ ), high levels of missing data (capture rate  $< 95\%$ ) or low MAF ( $< 1\%$ ). Twelve-lead ECG recordings (Siemens-Sicard 440; <http://www.brightstudy.ac.uk/info/sop04.html>), which produces an automated measurement of the *QT* interval, were available for all subjects. All data were transferred from each recruitment centre by electronic modem to electrophysiologists from the West of Scotland Primary Prevention Study (Professor Peter MacFarlane) for central reporting. Thirteen hundred and ninety two individuals remained in the analysis after exclusion of those having ischemic disease, stroke, or bypass, atrial fibrillation, or *QRS* duration  $> 120$  ms and having full covariate information.

**The DCCT/EDIC Study.** The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study was a clinical trial and follow-up of subjects with type 1 diabetes. Fourteen hundred forty one patients with type 1 diabetes were recruited for the DCCT [60] and followed-up in EDIC [61]. Genome-wide genotyping in subjects from the DCCT/EDIC was performed using the Illumina 1 M beadchip assay (Illumina, San Diego, USA) of which 841,342 SNPs with a MAF  $> 1\%$  were subsequently analyzed statistically. Autosomal SNPs showing significant association with gender ( $p < 10^{-8}$ ) or deviating from HWE ( $p < 10^{-8}$ ) were excluded from the analysis. To reduce the possibility of population stratification, we limited the analysis to individuals who self-identified as white, and excluded individuals who were determined to be admixed between Caucasian and other ethnic groups through population genetic approaches, using Eigenstrat [59] seeding with genotype data from the three major populations genotyped in HapMap Phase II [62].

Twelve-lead resting ECGs were obtained by a certified technician or research nurse at 29 clinics, measured digitally and read according to the revised Minnesota Code at the Central ECG Reading Unit (University of Minnesota, under the direction of Dr. Richard S. Crow) [63]. In brief, at least 1 full min of ECG tracing was obtained consisting of 5 s of each of the leads (I, II, III, aVR, aVL, aVF, and V1–V6). Additionally, individuals having ischemic disease, stroke, or bypass, atrial fibrillation, or *QRS* duration  $> 120$  ms were excluded, therefore in total 323 individuals were excluded from the analysis.

### Imputation

As all three cohorts used different platforms for genome wide genotyping, non-genotyped autosomal SNPs were imputed. For TwinsUK and BRIGHT individuals imputation was performed using Phase II CEU HapMap data (release 22, build 36) as the reference database using IMPUTE version 0.3.2 [64]. For DCCT/EDIC individuals imputation was performed using Phase II CEU HapMap data (release 22, build 36) using MACH v 1.0.16 [62,65].

### Statistical Analyses

Using regression analysis, we adjusted *QT* interval for RR interval, age, sex, height, body mass index, hypertension, and *QT* interval shortening or prolonging drugs (if available) within each cohort. For the TwinsUK sample, an extra covariate for the method of measurement (automatically vs. manually scored) of the *QT* interval was incorporated. Standardized *QT* interval residuals were used for further analyses. For the TwinsUK and BRIGHT cohorts, association between standardized corrected *QT* interval data and autosomal SNPs was tested with an F-test in SNPTEST version 1.1.4 using an additive model and the proper option to account for the uncertainty of the genotypes that were imputed [64]. As the TwinsUK cohort data consisted partly of dizygotic twins, the variances of the regression coefficients were corrected

for the sibship relations using the Huber-White method for robust variance estimation in R [66,67]. In the DCCT/EDIC cohort, SNPs were tested for association with corrected QT interval using an additive model in MACH2QTL version 1.04 [62,65]. Genomic control was performed to check for population stratification [27].

A meta-analysis was conducted in R using the inverse variance-weighted fixed effects method on the beta estimates relative to a consistent reference allele to combine the results of TwinsUK, BRIGHT, and DCCT/EDIC cohorts (own software). Only SNPs with  $MAF > 1\%$ ,  $P > 10^{-6}$  for the HWE test calculated using the genotypes inferred after imputation by maximum likelihood expectation and an imputation quality score reflecting the observed by expected variance ratio  $> 0.5$  for TwinsUK and BRIGHT (IMPUTE proper\_info) and  $> 0.3$  for DCCT/EDIC (MACH  $r^2$ ) were included in the analysis. Heterogeneity of observed effects was tested by the Q test [33].

### QTSCD and QTGEN 'in silico' cohorts: description, genotyping and analysis

The QTSCD consortium conducted a meta-analysis of results of GWAS on QT interval from the ARIC, SardiNIA, KORA, GenNOVA and HNR cohorts comprising in total 15,842 individuals (in press [26]). The QTGEN consortium combined the results of GWAS on QT interval from the Framingham Heart Study, the Rotterdam Study, and the Cardiovascular Health study in a meta-analysis including in total 13,685 individuals (in press [25]). Both studies imputed genotype data in order to facilitate the comparison of genotyping results across different platforms. Further details of materials and methods of both consortia can be found elsewhere (in press [25,26]).

We performed a meta-analysis combining our results with those of the QTSCD and the QTGEN consortia for our five most statistically significant independent SNPs using methods as described above.

### Supporting Information

**Figure S1** PLN protein-protein interaction network. This protein-protein interaction network was generated by the STRING program (<http://string.embl.de>) after querying the PLN gene using a high confidence score (0.700). Data supporting the interactions illustrated were derived from experimental studies (purple lines), databases (blue lines) and text mining (green lines). The genes that are involved in the calcium signaling pathway are indicated in red, the nodes with purple stars indicate the genes that are associated with cardiovascular diseases as based on functional annotation by DAVID (<http://david.abcc.ncifcrf.gov>). Only for large nodes are 3D protein structures available in STRING. The colour of the nodes does not encode any information. Found at: doi:10.1371/journal.pone.0006138.s001 (0.22 MB DOC)

**Figure S2** PLN co-expression network. This network is retrieved from the gene co-expression database COXPRESdb (<http://coxpresdb.hgc.jp>) using the PLN Entrez ID (5350) as the query. The co-expression network is drawn based on rank of correlation from 123 Human microarray experiments released by the NCBI GEO database. The bold grey lines indicate average ranks from 1 to 4. The normal light gray lines indicate average ranks from 5 to 29. The orange lines indicate conserved co-expression based on evidence from the NCBI HomoloGene database and COXPRESdb. The gene names in red indicate muscle or heart specific

expression and nodes with purple stars refer to genes that are associated with cardiovascular diseases as based on functional annotation by DAVID (<http://david.abcc.ncifcrf.gov>). For large nodes 3D protein structures are available in STRING. The colour of the nodes does not encode any information.

Found at: doi:10.1371/journal.pone.0006138.s002 (0.13 MB DOC)

**Figure S3** Tissue-specific expression of PLN. (source: co-expressed gene database COXPRESdb: <http://coxpresdb.hgc.jp>. Calculation is based on the 123 human microarray experiments released by NCBI GEO version 7.)

Found at: doi:10.1371/journal.pone.0006138.s003 (0.04 MB DOC)

**Table S1** All SNPs with  $p < 10^{-6}$  for the additive model from the meta-analysis of the TwinsUK, BRIGHT and DCCT/EDIC cohorts.

Found at: doi:10.1371/journal.pone.0006138.s004 (0.05 MB XLS)

**Table S2** Most significant SNPs from the meta-analysis of TwinsUK, BRIGHT and DCCT/EDIC cohorts within an area 20 kb upstream and downstream of the 11 known candidate genes for LQTS and SQTS.

Found at: doi:10.1371/journal.pone.0006138.s005 (0.04 MB DOC)

**Appendix S1** Consortium members and affiliations

Found at: doi:10.1371/journal.pone.0006138.s006 (0.06 MB DOC)

### Acknowledgments

**For Twins UK:** Analyses were performed on the Genetic Cluster Computer, which is financed by an NWO Medium Investment grant 480-05-003 and by the Faculty of Psychology and Education of the VU University, Amsterdam, The Netherlands. Genotyping of TwinsUK samples: We thank the staff from the Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation, Quality Control and Genotyping led by Leena Peltonen and Panos Deloukas; Le Centre National de Génotypage, France, led by Mark Lathrop, for genotyping; Duke University, North Carolina, USA, led by David Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki, led by Aarno Palotie.

**For the BRIGHT study:** We are extremely grateful to all the patients who participated in the study and the BRIGHT nursing team, and to Abiodun Onipinla.

**For the DCCT/EDIC study:** The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health.

**For QTSCD:** We gratefully acknowledge all participants in the community based studies of ARIC, KORA, SardiNIA, GenNOVA and Heinz Nixdorf Recall Study, and all Study investigators for study design and helpful discussion.

**For QTGEN:** The QTGEN consortium thanks the participants of the Framingham Heart Study, Rotterdam Study and Cardiovascular Health Study.

### Author Contributions

Conceived and designed the experiments: CW MJC HS AP PM YJ. Analyzed the data: IMN CW SJN DW JF NS EZ LVW MDT HS AP PM YJ. Wrote the paper: IMN MDT MJC HS AP PM YJ. GWAS genotyping team: RG PD. Data collection and phenotyping: IS DZ CD MF NJS JC MB AD GML CNC FWA TDS NC SJ. In silico data: ME KR PdB AP SS DEA.



## References

- Patel ND, Singh BK, Mathew ST (2006) The heterogeneous spectrum of the long QT syndrome. *Eur J Intern Med* 17: 235–240.
- Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbroucke JP, et al. (1991) QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. *Circulation* 84: 1516–1523.
- Dekker JM, Crow RS, Hannan PJ, Schouten EG, Folsom AR (2004) Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. *J Am Coll Cardiol* 43: 565–571.
- Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, et al. (1992) Sex differences in the evolution of the electrocardiographic QT interval with age. *Can J Cardiol* 8: 690–695.
- Luo S, Michler K, Johnston P, Macfarlane PW (2004) A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. *J Electrocardiol* 37 Suppl: 81–90.
- Reardon M, Malik M (1996) QT interval change with age in an overtly healthy older population. *Clin Cardiol* 19: 949–952.
- Yang H, Elko P, LeCarpentier GL, Baga J, Fromm B, et al. (1994) Sex differences in the rate of cardiac repolarization. *J Electrocardiol* 27 Suppl: 72–73.
- Roden DM (2004) Drug-induced prolongation of the QT interval. *N Engl J Med* 350: 1013–1022.
- Busjahn A, Knoblauch H, Faulhaber HD, Boeckel T, Rosenthal M, et al. (1999) QT interval is linked to 2 long-QT syndrome loci in normal subjects. *Circulation* 99: 3161–3164.
- Carter N, Snieder H, Jeffery S, Saumarez R, Varma C, et al. (2000) QT interval in twins. *J Hum Hypertens* 14: 389–390.
- Dalageorgou C, Ge D, Jamshidi Y, Nolte IM, Riese H, et al. (2008) Heritability of QT interval: how much is explained by genes for resting heart rate? *J Cardiovasc Electrophysiol* 19: 386–391.
- Pietila E, Fodstad H, Niskasaari E, Laitinen PP, Swan H, et al. (2002) Association between HERG K897T polymorphism and QT interval in middle-aged Finnish women. *J Am Coll Cardiol* 40: 511–514.
- Newton-Cheh C, Guo CY, Larson MG, Musone SL, Surti A, et al. (2007) Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. *Circulation* 116: 1128–1136.
- Pfeufer A, Jalilzadeh S, Perz S, Mueller JC, Hinterseer M, et al. (2005) Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. *Circ Res* 96: 693–701.
- Bezzina CR, Verkerk AO, Busjahn A, Jeron A, Erdmann J, et al. (2003) A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. *Cardiovasc Res* 59: 27–36.
- Gouas L, Nicaud V, Chaouch S, Berthet M, Forhan A, et al. (2007) Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. *Eur J Hum Genet* 15: 974–979.
- Gouas L, Nicaud V, Berthet M, Forhan A, Tiret L, et al. (2005) Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population. *Eur J Hum Genet* 13: 1213–1222.
- Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, et al. (2006) A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. *Nat Genet* 38: 644–651.
- Post W, Shen H, Damcott C, Arking DE, Kao WH, et al. (2007) Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the old order Amish. *Hum Hered* 64: 214–219.
- Aarnoudse AJ, Newton-Cheh C, de Bakker PI, Straus SM, Kors JA, et al. (2007) Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. *Circulation* 116: 10–16.
- Tobin MD, Kahonen M, Braund P, Nieminen T, Hajat C, et al. (2008) Gender and effects of a common genetic variant in the NOS1 regulator NOS1AP on cardiac repolarization in 3761 individuals from two independent populations. *Int J Epidemiol* 37: 1132–1141.
- Lehtinen AB, Newton-Cheh C, Ziegler JT, Langefeld CD, Freedman BI, et al. (2008) Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study. *Diabetes* 57: 1108–1114.
- Eijgelsheim M, Aarnoudse AL, Rivadencira F, Kors JA, Witteman JC, et al. (2009) Identification of a common variant at the NOS1AP locus strongly associated to QT-interval duration. *Hum Mol Genet* 18: 347–357.
- Raitakari OT, Blom-Nyholm J, Koskinen TA, Kahonen M, Viikari JS, et al. (2009) Common variation in NOS1AP and KCNH2 genes and QT interval duration in young adults. The Cardiovascular Risk in Young Finns Study. *Ann Med* 41: 144–151.
- Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, et al. (2009) Common variants at ten loci influence QT interval duration in the QTGEN Study. *Nat Genet* 41: 399–406.
- Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, et al. (2009) Common variants at ten loci modulate the QT interval duration in the QTSCD Study. *Nat Genet* 41: 407–414.
- Devlin B, Roeder K (1999) Genomic control for association studies. *Biometrics* 55: 997–1004.
- Ge D, Zhang K, Need AC, Martin O, Fellay J, et al. (2008) WGAViewer: software for genomic annotation of whole genome association studies. *Genome Res* 18: 640–643.
- Pe'er I, Yelensky R, Altshuler D, Daly MJ (2008) Estimation of the multiple testing burden for genome-wide association studies of nearly all common variants. *Genet Epidemiol* 32: 381–385.
- Dudbridge F, Gusnanto A (2008) Estimation of significance thresholds for genome-wide association scans. *Genet Epidemiol* 32: 227–234.
- Marjamaa A, Newton-Cheh C, Porthan K, Reunanen A, Lahermo P, et al. (2008) Common candidate gene variants are associated with QT interval duration in the general population. *J Intern Med*.
- Goring HH, Terwilliger JD, Blangero J (2001) Large upward bias in estimation of locus-specific effects from genome-wide scans. *Am J Hum Genet* 69: 1357–1369.
- Cochran WG (1954) The combination of estimates from different experiments. *Biometrics* 10: 101–129.
- Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, et al. (1994) Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. *Circ Res* 75: 401–409.
- Luo W, Wolska BM, Grupp IL, Harrer JM, Haghghi K, et al. (1996) Phospholamban gene dosage effects in the mammalian heart. *Circ Res* 78: 839–847.
- Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, et al. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. *Science* 299: 1410–1413.
- Minamisawa S, Sato Y, Tatsuguchi Y, Fujino T, Imamura S, et al. (2003) Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. *Biochem Biophys Res Commun* 304: 1–4.
- Dash R, Frank KF, Carr AN, Moravec CS, Kranias EG (2001) Gender influences on sarcoplasmic reticulum Ca<sup>2+</sup>-handling in failing human myocardium. *J Mol Cell Cardiol* 33: 1345–1353.
- Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, et al. (1995) Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. *Circulation* 92: 778–784.
- Haghghi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, et al. (2006) A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. *Proc Natl Acad Sci U S A* 103: 1388–1393.
- Wu Y, MacMillan LB, McNeill RB, Colbran RJ, Anderson ME (1999) CaM kinase augments cardiac L-type Ca<sup>2+</sup> current: a cellular mechanism for long QT arrhythmias. *Am J Physiol* 276: H2168–H2178.
- del Monte F, Lebeche D, Guerrero JL, Tsuji T, Doye AA, et al. (2004) Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. *Proc Natl Acad Sci U S A* 101: 5622–5627.
- Xu Y, Zhang Z, Timofeyev V, Sharma D, Xu D, et al. (2005) The effects of intracellular Ca<sup>2+</sup> on cardiac K<sup>+</sup> channel expression and activity: novel insights from genetically altered mice. *J Physiol* 562: 745–758.
- Li J, Marionneau C, Zhang R, Shah V, Hell JW, et al. (2006) Calmodulin kinase II inhibition shortens action potential duration by upregulation of K<sup>+</sup> currents. *Circ Res* 99: 1092–1099.
- Xu KY, Huso DL, Dawson TM, Bredt DS, Becker LC (1999) Nitric oxide synthase in cardiac sarcoplasmic reticulum. *Proc Natl Acad Sci U S A* 96: 657–662.
- Loyer X, Gomez AM, Milliez P, Fernandez-Velasco M, Vangheluwe P, et al. (2008) Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling. *Circulation* 117: 3187–3198.
- Zhang YH, Zhang MH, Sears CE, Emanuel K, Redwood C, et al. (2008) Reduced phospholamban phosphorylation is associated with impaired relaxation in left ventricular myocytes from neuronal NO synthase-deficient mice. *Circ Res* 102: 242–249.
- DeWitt MM, MacLeod HM, Soliven B, McNally EM (2006) Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. *J Am Coll Cardiol* 48: 1396–1398.
- van Spaendonck-Zwarts KY, van den Berg MP, van Tintelen JP (2008) DNA analysis in inherited cardiomyopathies: current status and clinical relevance. *Pacing Clin Electrophysiol* 31 Suppl 1: S46–S49.
- Marjamaa A, Newton-Cheh C, Porthan K, Reunanen A, Lahermo P, et al. (2008) Common candidate gene variants are associated with QT interval duration in the general population. *J Intern Med*.
- Becker ML, Visser LE, Newton-Cheh C, Hofman A, Uitterlinden AG, et al. (2009) A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers. *Br J Clin Pharmacol* 67: 61–67.
- Becker ML, Aarnoudse AJ, Newton-Cheh C, Hofman A, Witteman JC, et al. (2008) Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. *Pharmacogenet Genomics* 18: 591–597.

53. Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, et al. (2008) Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. *Lancet* 371: 1505–1512.
54. Teo YY, Inouye M, Small KS, Gwilliam R, Deloukas P, et al. (2007) A genotype calling algorithm for the Illumina BeadArray platform. *Bioinformatics* 23: 2741–2746.
55. Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. *Genetics* 155: 945–959.
56. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81: 559–575.
57. Andrew T, Hart DJ, Snieder H, de Lange M, Spector TD, et al. (2001) Are twins and singletons comparable? A study of disease-related and lifestyle characteristics in adult women. *Twin Res* 4: 464–477.
58. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447: 661–678.
59. Patterson N, Price AL, Reich D (2006) Population structure and eigenanalysis. *PLoS Genet* 2: e190.
60. The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. The DCCT Research Group. *Diabetes* 35: 530–545.
61. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. *Diabetes Care* 22: 99–111.
62. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. *Nature* 449: 851–861.
63. Paterson AD, Rutledge BN, Cleary PA, Lachin JM, Crow RS (2007) The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. *Diabetes Care* 30: 2107–2112.
64. Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet* 39: 906–913.
65. Li Y, Abecasis GR (2006) Mach 1.0: Rapid Haplotype Reconstruction and Missing Genotype Inference. *Am J Hum Genet* S. pp 2290.
66. Huber PJ (1967) The behavior of maximum likelihood estimates under non-standard conditions. *Proc Fifth Berkeley Symposium Math Stat* 1: 221–223.
67. White H (1982) Maximum Likelihood Estimation of Misspecified Models. *Econometrica* 50: 1–26.